



A REVIEW OF MUCORMYCOSIS: A THREAT IN THE COVID-19 PANDEMIC

Dr Lakshminarayana SA¹, Dr.Vamseedhar Annam², Dr.K.Bindumadhuri³,

Dr Shalini Jiwan Chahande⁴, Dr Korla Swapnavahini⁵

¹Professor and Head, Department of Microbiology, Rajarajeswari Medical College and Hospital

²Professor of Pathology, Rajarajeswari Medical College and Hospital, Bangalore

³Assistant Professor, Krupanidhi College of Pharmacy, Bengaluru

⁴Associate Professor and Head Department of Biochemistry, Seth Kesarimal Porwal College of Arts and Science and Commerce, Kamptee, Affiliated to Rashtrasant Tukadoji Maharaj Nagpur University, Maharashtra

⁵Assistant Professor, Department of Biotechnology, Dr B.R. Ambedkar University, Srikakulam, Etcherla - 532410

Abstract

India has been devastated by the second wave of Coronavirus Disease 2019 (COVID-19) in early 2021. The number of severe cases has significantly increased as daily infection rates have risen alarmingly. Inadequate health infrastructure and an excessive demand for hospital beds, medications, vaccines, and oxygen have plagued the nation. Adding more weight to such a difficult circumstance, mucormycosis, an obtrusive parasitic contamination, has seen an unexpected flood in patients with Coronavirus. The most prevalent form that has been observed is the rhino-orbital-cerebral one. Particularly, approximately three-quarters of them received corticosteroids to treat COVID-19 because they had diabetes as a predisposing comorbidity. Potential systems might include insusceptible and fiery cycles. Diabetes, when combined with Coronavirus incited foundational insusceptible change, will in general reason diminished resistance and an expanded gamble of optional diseases. Since exhaustive information on this lethal sharp contamination are developing against the setting of a significant pandemic, counteraction procedures basically include overseeing comorbid conditions in high-risk gatherings. Surgical debridement and antifungal therapy with Amphotericin B and selected azoles were the primary treatment options. To correctly diagnose the infection, characterize the clinical presentation, comprehend the pathogenesis, and monitor the course of the disease, a number of India-specific clinical guidelines have emerged. The most comprehensive is Code Mucor, which offers a straightforward but dependable staging system for the rhino-orbital-cerebral form. An organizing framework has as of late been proposed, and a committed library has been begun. We conduct a thorough analysis of the most recent data and recommendations regarding COVID-19-associated mucormycosis in India in this critical review.

Keywords: COVID-19, Corticosteroid, Diabetes mellitus, Fungus, Mucormycosis

1. Introduction

As of November 20, 2021, more than 255 million confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had been identified worldwide, and more than 5 million deaths had been reported. Although respiratory tract symptoms and fever were the most common clinical presentations among symptomatic patients, extra-pulmonary involvements by COVID-19 include cardiac, gastrointestinal, hepatic, renal, neurological, olfactory, gustatory, ocular, cutaneous, and hematological symptoms infections like flu, Covid, rhinovirus/enterovirus, parainfluenza,

metapneumovirus, and human immunodeficiency infection, and parasites, for example, *Aspergillus* spp. notwithstanding these co-microorganisms, many instances of mucormycosis among Coronavirus patients have been accounted for recently. Mucormycosis is an uncommon however forceful contagious illness and it basically influences patients with ineffectively controlled diabetes mellitus and seriously immunocompromised patients. rather than aspergillosis, mucormycosis was seldom detailed following viral infection. as of now, the investigations and information about Coronavirus related with mucormycosis (CAM) have been restricted. To provide up-to-date information, we conducted a comprehensive literature review on mucormycosis in COVID-19 patients.

The study of disease transmission

Since the flare-up of Coronavirus, an ever increasing number of instances of CAM have been reported. In UK, the posthumous investigation of 10 a few deadly Coronavirus cases in the early pandemic (between 1 and April 30, 2020) showed one patient who had surprising scattered mucormycosis including the lungs and brain. In US, Placik et al. reported a COVID-19-related fatal case of mucormycosis in Arizona with necrosing pulmonary infections and a bronchopleural fistula²⁵. demonstrated a diabetic patient with COVID-19-associated rhino-orbital mucormycosis. In Brazil, Monte Junio et al. showed a surprising instance of gastric mucormycosis in an older patient with Coronavirus 19. In Italy, Paserol et al. As of May 28, 2021, at least 14, 872 cases of CAM have been found in India, with the state of Gujarat having the highest incidence, with at least 3726 cases, followed by the state of Maharashtra.³⁷ The same trend was reported in another large retrospective study of 2826 patients with COVID-19 associated rhino-orbital-cerebral mucormycosis, in which the states of Gujarat (22%) and Maharashtra (21%) had the highest cases.³⁸ At the same time, In a review testing the in-vitro development of *Rhizopus oryzae*, a typical etiologic specialist of mucormycosis, in DKA serum, the acidotic circumstances (pH 7.3-6.6) of serum would diminish the limit of transferrin to tie iron, in this way offering the unbound iron in the DKA serum to help the lavish development of *R. oryzae*. Clinical and animal model data have demonstrated that the presence of elevated available serum iron predisposes the host to mucormycosis due to the critical role of Mucorales' ability to acquire host iron as a virulence factor. *Rhizopus* invades the epithelium via fungal spore coat proteins (CoH) binding to the host receptor of glucose-regulated protein 78 (GRP78) on the nasal and alveolar epithelial cells. Indirectly, BHB reduced transferrin's capacity to bind iron, thereby raising serum iron levels. In addition to administering corticosteroids as part of routine treatment for COVID-19 patients, this combination can further upregulate CoH3 and nasal GRP78,⁶⁰ thereby entangling the fungal cells within the rhino-orbital epithelium and causing subsequent invasive diseases. These BHB-created acidotic serum conditions very incline toward mucormycosis, however not to aspergillosis.

Communications between Coronavirus and mucormycosis

Most instances of mucormycosis are transiently connected to Coronavirus 19. The flood in the quantity of instances of CAM is pertinent to natural qualities and general glucocorticoid use for extreme Coronavirus cases, notwithstanding a past notable segment component of unfortunate control for diabetes mellitus particularly with DKA. The foundational utilization of corticosteroids is a situation with two sides in the treatment for cytokine storm and setting off for mucormycosis in the Coronavirus patients that requires basic care. The mix of steroid treatment and diabetes mellitus can expand immunosuppression and hyperglycemia, expanding the gamble of mucormycosis. Most cases were accounted for from India in the literature. Despite the fact that a somewhat high local predominance in India, a 2.1-overlay ascend in mucormycosis during the Coronavirus pandemic than earlier year was noted. The middle time span between Coronavirus determination and the principal proof of a mucormycosis contamination was 7-15 days.

Instances of mucormycosis may happen in Coronavirus patients without diabetes mellitus and just with gentle to-direct illnesses outside escalated care units, as detailed in the Netherlands. Albeit

extreme or basic Coronavirus in inadequately controlled diabetic patients is the absolute best tempest for mucormycosis, getting corticosteroids could add to the development of mucormycosis in Coronavirus patients even without basic seriousness and a gamble comorbidity.

High includes of Mucorales spores in both the indoor and open air conditions are conceivable extra inclining factors. The natural elements could add to the "problem area" districts of CAM on the planet, like the urban communities of Bangalore, Ahmedabad, Jaipur, and Mumbai in India. Different parts of India's soil samples contained mucorales, the most common of which was *Rhizopus arrhizus* (24.6 percent), followed by *Lichtheimia* spp. *Cunninghamella* spp. (23.2%) (21.7 percent), *Rhizopus microsporus* (14 percent), and *Apophysomyces* spp. However, there are few studies that link environmental levels of zygomycete sporangiospores and zygomycosis, particularly in areas where zygomycosis is common. Additionally, therapy with an IL-6 receptor antagonist may increase the risk of fungal infections, and severe COVID-19 disease is linked to an increase in pro-inflammatory markers like interleukin (IL)-1 and IL-6. COVID-19 may affect the immune system, resulting in lymphopenia.

Outcomes

CAM-related mortality and morbidity remain high. Buil et al. detailed that three of 4 CAM cases created in the ICU and three passings happened in the Netherlands. In a progression of 187 CAM cases in India, the revealed generally mortality was 37.4% (70/187) and 44.1% (75/170) inside 6 and 12 weeks respectively. The death rates were considerably higher in non-predominant districts (>50%-100 percent in US and the European nations) than pervasive locales (around 40%-half in the center East and Egypt) and most minimal (13%) in India. The largest study of 2826 patients with COVID-19 associated rhino-orbital-cerebral mucormycosis in India reported that all-cause mortality was 14% (n = 305) of 2128 patients with available outcome data. However, the prognosis of mucormycosis may differ depending on the site of involvement. thrombosis of the superior ophthalmic vein or occlusion of the central retinal or ophthalmic artery; inclusion of prevalent orbital gap, second rate orbital crevice, orbital zenith, loss of vision; stage 3d: bilateral involvement in the orbits; paranasal sinus debridement and orbital exenteration could significantly reduce the mortality rate in patients with stage 4 of intracranial extension (52 percent versus 39 percent, p 0.05), according to this study.

Conclusion

The emergence of CAM during the COVID-19 pandemic has raised serious concerns, particularly in India. Corticosteroid use and uncontrolled diabetes mellitus with DKA are the most common conditions among CAM patients. The most common site of involvement is the rhino-orbital-cerebral region, but CAM can also affect the lungs, skin, and stomach. The key to successful CAM patient care is high suspicion and early diagnosis. First-line high-dose liposomal amphotericin B and the right surgical treatment can help improve the outcome of CAM, despite the poor prognosis.

References

- Ahmadikia K., Hashemi S.J., Khodavaisy S., Getso M.I., Alijani N., Badali H., et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. *Mycoses*. 2021;64:798–808.
- Ajmal S., Mahmood M., Abu Saleh O., Larson J., Sohail M.R. Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts. *Infection*. 2018;46:555–558.
- Alekseyev K., Didenko L., Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. *J Med Cases*. 2021;12:85–89.
- Alhumaid S., Al Mutair A., Al Alawi Z., Alshawi A.M., Alomran S.A., Almuhanha M.S., et al. Coinfections with bacteria, fungi, and respiratory viruses in patients with SARS-CoV-2: a systematic review and meta-analysis. *Pathogens*. 2021;10:809.

- Alqarihi A., Gebremariam T., Gu Y., Swidergall M., Alkhazraji S., Soliman S.S.M., et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. *mBio*. 2020;11 e01087-20.
- Arana C., Cuevas Ramírez R.E., Xipell M., Casals J., Moreno A., Herrera S., et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. *Transpl Infect Dis*. 2021;23
- Arendrup M.C., Jensen R.H., Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. *Antimicrob Agents Chemother*. 2015;59:7735–7742.
- Artis W.M., Fountain J.A., Delcher H.K., Jones H.E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. *Diabetes*. 1982;31:1109–1114.
- Ashkenazi-Hoffnung L., Bilavsky E., Levy I., Grisaru G., Sadot E., Ben-Ami R., et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. *Pediatr Infect Dis J*. 2020;39:718–724.
- Ashour M.M., Abdelaziz T.T., Ashour D.M., Askoura A., Saleh M.I., Mahmoud M.S. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. *J Neuroradiol*. 2021;48:319–324.
- Bayram N., Ozsaygılı C., Sav H., Tekin Y., Gundogan M., Pangal E., et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J Ophthalmol*. 2021;65:515–525.
- Bellanger A.P., Navellou J.C., Lepiller Q., Brion A., Brunel A.S., Millon L., et al. Mixed mold infection with *Aspergillus fumigatus* and *Rhizopus microsporus* in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. *Infect Dis News*. 2021;51:633–635.
- Buil J.B., van Zanten A.R.H., Bentvelsen R.G., Rijpstra T.A., Goorhuis B., van der Voort S.R., et al. Case series of four secondary mucormycosis infections in COVID-19 patients, The Netherlands, December 2020 to May 2021. *Euro Surveill*. 2021;26:2100510.
- Chakrabarti A., Singh R. Mucormycosis in India: unique features. *Mycoses*. 2014;57(Suppl 3):85–90.
- Chen W.C., Lai Y.C., Lin C.H., Zheng J.F., Hung W.C., Wang Y.J., et al. First COVID-19 mortality case in Taiwan with bacterial co-infection by national surveillance of critically ill patients with influenza-negative pneumonia. *J Microbiol Immunol Infect*. 2020;53:652–656.
- Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., Hochhegger B., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. *Lancet Infect Dis*. 2019;19:e405–e421.
- Dallalzadeh L.O., Ozzello D.J., Liu C.Y., Kikkawa D.O., Korn B.S. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit*. 2021;1–4. doi: 10.1080/01676830.2021.
- Ellsworth M., Ostrosky-Zeichner L. Isavuconazole: mechanism of action, clinical efficacy, and resistance. *J Fungi (Basel)* 2020;6:324.
- Fouad Y.A., Abdelaziz T.T., Askoura A., Saleh M.I., Mahmoud M.S., Ashour D.M., et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. *Front Med*. 2021;8:645270.
- Garg D., Muthu V., Sehgal I.S., Ramachandran R., Kaur H., Bhalla A., et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. *Mycopathologia*. 2021;186:289–298.
- Gebremariam T., Lin L., Liu M., Kontoyiannis D.P., French S., Edwards J.E. Jr., et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *J Clin Invest*. 2016;126:2280–2294.
- Gebremariam T., Liu M., Luo G., Bruno V., Phan Q.T., Waring A.J., et al. CotH3 mediates fungal invasion of host cells during mucormycosis. *J Clin Invest*. 2014;124:237–250.
- Gumashta J., Gumashta R. COVID19 associated mucormycosis: is GRP78 a possible link? *J Infect Public Health*. 2021;14:1351–1357.

- Hanley B., Naresh K.N., Roufousse C., Nicholson A.G., Weir J., Cooke G.S., et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *Lancet Microbe*. 2020;1:e245–e253.
- Honavar S.G. Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. *Indian J Ophthalmol*. 2021;69:1361–1365.
- Ibrahim A.S. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. *Mycoses*. 2014;57(Suppl 3):13–17.
- Ibrahim A.S., Gebremariam T., Lin L., Luo G., Hussein M.I., Skory C.D., et al. The high affinity iron permease is a key virulence factor required for *Rhizopus oryzae* pathogenesis. *Mol Microbiol*. 2010;77:587–604.
- Ilharco M., Pereira C.M., Moreira L., Proença A.L., do Carmo Fevereiro M., Lampreia F., et al. Rhinoorbital mucormycosis in the immunocompetent: experience with isavuconazole. *IDCases*. 2019;18
- Imran M., Alshrari S.A., Tauseef M., Khan S.A., Hudu S.A., Abida Mucormycosis medications: a patent review. *Expert Opin Ther Pat*. 2021;31:1059–1074.
- Ismail W.F., Abdelazim M.H., Eldsoky I., Ibrahim A.A., Alsobky M.E., Zafan E., et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. *Am J Otolaryngol*. 2021;42:103080.
- John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. *J Fungi (Basel)* 2021;7:298.
- Johnson A.K., Ghazarian Z., Cendrowski K.D., Persichino J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. *Med Mycol Case Rep*. 2021;32:64–67.
- Joshi A.R., Muthe M.M., Patankar S.H., Athawale A., Achhapalia Y. CT and MRI findings of invasive mucormycosis in the setting of COVID-19: experience from a single center in India. *AJR Am J Roentgenol*. 2021;217:1431–1432.
- Kanwar A., Jordan A., Olewiler S., Wehberg K., Cortes M., Jackson B.R. A fatal case of *Rhizopus azygosporus* pneumonia following COVID-19. *J Fungi (Basel)* 2021;7:174.
- Karimi-Galougahi M., Arastou S., Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19) *Int Forum Allergy Rhinol*. 2021;11:1029–1030.
- Khatri A., Chang K.M., Berlin I., Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - case report and review of literature. *J Mycol Med*. 2021;31:101125.
- Krishna V., Morjaria J., Jalandari R., Omar F., Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. *IDCases*. 2021;25
- Lai C.C., Ko W.C., Lee P.I., Jean S.S., Hsueh P.R. Extra-respiratory manifestations of COVID-19. *Int J Antimicrob Agents*. 2020;56:106024.
- Lai C.C., Liu Y.H., Wang C.Y., Wang Y.H., Hsueh S.C., Yen M.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. *J Microbiol Immunol Infect*. 2020;53:404–412.
- Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55:105924.
- Lai C.C., Wang C.Y., Hsueh P.R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? *J Microbiol Immunol Infect*. 2020;53:505–512.
- Lai C.C., Yu W.L. COVID-19 associated with pulmonary aspergillosis: a literature review. *J Microbiol Immunol Infect*. 2021;54:46–53.
- Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect*. 2020;26:1622–1629.

- Maini A., Tomar G., Khanna D., Kini Y., Mehta H., Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. *Int J Surg Case Rep.* 2021;82:105957.
- Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. *Cureus.* 2020;12
- Mekonnen Z.K., Ashraf D.C., Jankowski T., Grob S.R., Vagefi M.R., Kersten R.C., et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. *Ophthalmic Plast Reconstr Surg.* 2021;37:e40–e80.
- Meshram H.S., Kute V.B., Chauhan S., Desai S. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. *Transpl Infect Dis.* 2021;23
- Miller R.P., Farrugia L., Leask J., Khalsa K., Khanna N., Melia L. Successful treatment of *Rhizopus arrhizus* rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement. *Med Mycol Case Rep.* 2021;32:39–42.
- Monte Junior E.S.D., Santos M., Ribeiro I.B., Luz G.O., Baba E.R., Hirsch B.S., et al. Rare and fatal gastrointestinal mucormycosis (*Zygomycosis*) in a COVID-19 patient: a case report. *Clin Endosc.* 2020;53:746–749.
- Moorthy A., Gaikwad R., Krishna S., Hegde R., Tripathi K.K., Kale P.G., et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-An unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. *J Maxillofac Oral Surg.* 2021;20:1–8.
- Musuuza J.S., Watson L., Parmasad V., Putman-Buehler N., Christensen L., Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. *PLoS One.* 2021;16
- Nehara H.R., Puri I., Singhal V., Ih S., Bishnoi B.R., Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. *Indian J Med Microbiol.* 2021;39:380–383.
- Pakdel F., Ahmadikia K., Salehi M., Tabari A., Jafari R., Mehrparvar G., et al. Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicenter study from Iran. *Mycoses.* 2021;64:1238–1252.
- Pal R., Singh B., Bhadada S.K., Banerjee M., Bhogal R.S., Hage N., et al. COVID-19-associated mucormycosis: an updated systematic review of literature. *Mycoses.* 2021;64:1452–1459.
- Pan J., Tsui C., Li M., Xiao K., de Hoog G.S., Verweij P.E., et al. First case of rhinocerebral mucormycosis caused by *Lichtheimia ornata*, with a review of *Lichtheimia* Infections. *Mycopathologia.* 2020;185:555–567.
- Pasero D., Sanna S., Liperi C., Piredda D., Branca G.P., Casadio L., et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. *Infection.* 2020;49:1055–1060.
- Patel A., Agarwal R., Rudramurthy S.M., Shevkani M., Xess I., Sharma R., et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. *Emerg Infect Dis.* 2021;27:2349–2359.
- Peng H., Xiao J., Wan H., Shi J., Li J. Severe gastric mycormycosis infection followed by cytomegalovirus pneumonia in a renal transplant recipient: a case report and concise review of the literature. *Transplant Proc.* 2019;51:556–560.
- Placik D.A., Taylor W.L., Wnuk N.M. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. *Radiol Case Rep.* 2020;15:2378–2381.
- Prakash H., Ghosh A.K., Rudramurthy S.M., Paul R.A., Gupta S., Negi V., et al. The environmental source of emerging *Apophysomyces variabilis* infection in India. *Med Mycol.* 2016;54:567–575.
- Rao R., Shetty A.P., Nagesh C.P. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. *Indian J Ophthalmol.* 2021;69:1627–1630.
- Raut A., Huy N.T. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? *Lancet Respir Med.* 2021;9:e77.

- Ravani S.A., Agrawal G.A., Leuva P.A., Modi P.H., Amin K.D. Rise of the phoenix: mucormycosis in COVID-19 times. *Indian J Ophthalmol.* 2021;69:1563–1568.
- Revannavar S.M., PS S., Samaga L., VK V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? *BMJ Case Rep.* 2021;14
- Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. *Clin Microbiol Infect.* 2009;15(Suppl 5):2–9.
- Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis.* 2005;41:634–653.
- Rudramurthy S.M., Hoenigl M., Meis J.F., Cornely O.A., Muthu V., Gangneux J.P., et al. ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries. *Mycoses.* 2021;64:1028–1037.
- Sai Krishna D., Raj H., Kurup P., Juneja M. Maxillofacial infections in Covid-19 era-actuality or the unforeseen: 2 Case reports. *Indian J Otolaryngol Head Neck Surg.* 2021:1–4. doi: 10.1007/s12070-021-02618-5.
- Saldanha M., Reddy R., Vincent M.J. Paranasal mucormycosis in COVID-19 patient. *Indian J Otolaryngol Head Neck Surg.* 2021:1–4. doi: 10.1007/s12070-021-02574-0.
- Sarkar S., Gokhale T., Choudhury S.S., Deb A.K. COVID-19 and orbital mucormycosis. *Indian J Ophthalmol.* 2021;69:1002–1004.
- Selarka L., Sharma A.K., Rathod G., Saini D., Patel S., Sharma V.K. Mucormycosis- A dreaded complication of Covid-19. *QJM.* 2021;114:670–671.
- Sen M., Honavar S.G., Bansal R., Sengupta S., Rao R., Kim U., et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2,826 patients in India - collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol.* 2021;69:1670–1692.
- Sen M., Lahane S., Lahane T.P., Parekh R., Honavar S.G. Mucor in a viral land: a tale of two pathogens. *Indian J Ophthalmol.* 2021;69:244–252.
- Seo Y.M., Hwang-Bo S., Kim S.K., Han S.B., Chung N.G., Kang J.H. Fatal systemic adenoviral infection superimposed on pulmonary mucormycosis in a child with acute leukemia: a case report. *Medicine (Baltim)* 2016;95
- Shafiq M., Ali Z., Ukani R., Brewer J. Isavuconazole: a promising salvage therapy for invasive mucormycosis. *Cureus.* 2018;10:e2547.
- Sharma S., Grover M., Bhargava S., Samdani S., Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol.* 2021;135:442–447.
- Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. *Diabetes Metab Syndr.* 2021;15:102146.
- Steinbrink J.M., Miceli M.H. Mucormycosis. *Infect Dis Clin.* 2021;35:435–452.
- Veisi A., Bagheri A., Eshaghi M., Rikhtehgar M.H., Rezaei Kanavi M., Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. *Eur J Ophthalmol.* 2021 11206721211009450.
- Waizel-Haiat S., Guerrero-Paz J.A., Sanchez-Hurtado L., Calleja-Alarcon S., Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. *Cureus.* 2021;13
- Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. *Am J Emerg Med.* 2021;42:264.e265–264.e268.
- World health organization. <https://covid19.who.int/>
- Zurl C., Hoenigl M., Schulz E., Hatzl S., Gorkiewicz G., Krause R., et al. Autopsy proven pulmonary mucormycosis due to *Rhizopus microsporus* in a critically ill COVID-19 patient with underlying hematological malignancy. *J Fungi (Basel)* 2021;7:88.